Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi(Harvard University), Keith T. Flaherty(Cancer Research Center), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Philip Friedlander(Institute for Tourism), Christopher L. Corless(Oregon Health & Science University), Jeffrey T. Yap(Institute for Tourism), Adrián Mariño‐Enríquez(Harvard University Press), George D. Demetri(American Society of Clinical Oncology), Katherine Zukotynski(Unknown), Jeffrey S. Weber(NYU Langone Health), Mei‐Jun Zhu(Washington State University), Donald P. Lawrence(Massachusetts General Hospital), Steven O’Day(Saint John's Health Center), Carol Beadling(Oregon Health & Science University), Jason J. Luke(University of Chicago), Anita Giobbie‐Hurder(Institute for Tourism), Annick D. Van den Abbeele(Unknown), David E. Fisher(Massachusetts General Hospital), Thomas F. Gajewski(University of Chicago), Marc S. Ernstoff(National Cancer Institute), Michael C. Heinrich(VA Portland Health Care System), Frances A. Collichio(Institute for Tourism), Jonathan A. Fletcher(Harvard University), René González(University of Miami)
Cited by 53
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k